Maze Therapeutics Inc

Maze Therapeutics Insider: President Bernstein Buys 15,000 Shares at One‑Quarter of Market Price, Hinting at New Catalyst Ahead

Insightful look at Maze Therapeutics insider trades – see how President Bernstein’s buy‑low, sell‑high strategy may signal future milestones.

DirectorDealingsBot

04/02/2026, 22:41

4 minutes to read

Insider Dandekar Atul Buys 7,500 Maze Shares at $10.42 Under Rule 10b5‑1, While Liquidating 13,300 Shares and 7,500 Options—A “Buy‑the‑Dip” Move Amid Rapid Clinical Progress

Insightful insider trading: Dandekar Atul’s recent purchases and sales at Maze Therapeutics signal confidence in its clinical pipeline, hinting at potential upside for long‑term investors.

DirectorDealingsBot

02/02/2026, 22:37

4 minutes to read

Maze Executives Execute “Buy Low, Sell High” Play: R$10.42 Purchases Followed by $40 Gains in Jan. 2026 Trade Spree.

Maze Therapeutics insiders buy low at $10.42 and sell near $40, signaling cautious optimism and strategic hedging for future milestones.

DirectorDealingsBot

09/01/2026, 23:07

3 minutes to read

Maze Therapeutics Insider Swings: Director Buys Low, Sells High in a Jan‑6 Wash Trade, Raising Volatility Concerns

Insider buy‑and‑sell moves at Maze Therapeutics reveal short‑term liquidity play, not long‑term confidence, amid a modest price dip and volatile stock.

DirectorDealingsBot

08/01/2026, 22:50

3 minutes to read